ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy

Annals of Surgery

Volumn 242, Issue 3, 2005, Pages 353-363

  Kebebew, Electron ^a,b,c   Peng, Miao ^b   Reiff, Emily ^b   Duh, Quan Yang ^b   Clark, Orlo H ^a,b   McMillan, Alex ^a   Prinz, Richard A ^c   Shaha, Ashok R ^c   McHenry, Christopher R ^c   Chen, Herbert ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; COMPLEMENTARY DNA; DISINTEGRIN; MESSENGER RNA; METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PADGEM PROTEIN; PROTEIN ADAMTS8; PROTEIN ECM1; PROTEIN TMPRSS4; PROTEINASE; SCLEROPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE;

ASPIRATION BIOPSY; CANCER INVASION; CANCER STAGING; CONFERENCE PAPER; CYTOLOGY; DIAGNOSTIC ACCURACY; DNA MICROARRAY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID NODULE; THYROIDECTOMY;

BIOPSY, FINE-NEEDLE; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; HUMANS; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SERINE ENDOPEPTIDASES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 24944513216     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000179623.87329.6b     Document Type: Conference Paper

References (94)

1. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3-27.
2. Silver RJ, Parangi S. Management of thyroid incidentalomas. Surg Clin North Am. 2004;84:907-919.
3. Uchino S, Noguchi S, Yamashita H, et al. Detection of asymptomatic differentiated thyroid carcinoma by neck ultrasonographic screening for familial nonmedullary thyroid carcinoma. World J Surg. 2004;10:14.
4. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328:553-559.
5. Greaves TS, Olvera M, Florentine BD, et al. Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer. 2000;90:335-341.
6. Baloch ZW, Fleisher S, LiVolsi VA, et al. Diagnosis of 'follicular neoplasm': a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 2002;26:41-44.
7. Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med. 1993;118:282-289.
8. Cersosimo E, Gharib H, Suman VJ, et al. 'Suspicious' thyroid cytologic findings: outcome in patients without immediate surgical treatment. Mayo Clin Proc. 1993;68:343-348.
9. Gharib H, Goellner JR, Johnson DA. Fine-needle aspiration cytology of the thyroid. A 12-year experience with 11,000 biopsies. Clin Lab Med. 1993;13:699-709.
10. Hooft L, Hoekstra OS, Boers M, et al. Practice, efficacy, and costs of thyroid nodule evaluation: a retrospective study in a Dutch university hospital. Thyroid. 2004;14:287-293.
11. Tuttle RM, Lemar H, Burch HB. Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. Thyroid. 1998;8:377-383.
12. Basu D, Jayaram G. A logistic model for thyroid lesions. Diagn Cytopathol. 1992;8:23-27.
13. Eldar S, Sabo E, Cohen A, et al. The value of histomorphometric nuclear parameters in the diagnosis of well differentiated follicular carcinomas and follicular adenomas of the thyroid gland. Histopathology. 1999;34:453-461.
14. Tyler DS, Winchester DJ, Caraway NP, et al. Indeterminate fine-needle aspiration biopsy of the thyroid: identification of subgroups at high risk for invasive carcinoma. Surgery. 1994;116:1054-1060.
15. Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res. 2004;64:3780-3789.
16. Aldred MA, Huang Y, Liyanarachchi S, et al. Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. J Clin Oncol. 2004;22:3531-3539.
17. Umbricht CB, Conrad GT, Clark DP, et al. Human telomerase reverse transcriptase gene expression and the surgical management of suspicious thyroid tumors. Clin Cancer Res. 2004;10:5762-5768.
18. Volante M, Bozzalla-Cassione F, Orlandi F, et al. Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Arch. 2004;444:309-312.
19. Weber KB, Shroyer KR, Heinz DE, et al. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol. 2004;122:524-531.
20. Marques AR, Espadinha C, Frias MJ, et al. Underexpression of peroxisome proliferator-activated receptor (PPAR)gamma in PAX8/PPARgamma-negative thyroid tumours. Br J Cancer. 2004;91:732-738.
21. Hibi Y, Nagaya T, Kambe F, et al. Is thyroid follicular cancer in Japanese caused by a specific t(2;3) (q13; p25) translocation generating Pax8-PPAR gamma fusion mRNA? Endocr J. 2004;51:361-366.
22. Nikiforova MN, Biddinger PW, Caudill CM, et al. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26:1016-1023.
23. Finley DJ, Zhu B, Barden CB, et al. Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg. 2004;240:425-436; discussion 436-427.
24. Finley DJ, Arora N, Zhu B, et al. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab. 2004;89:3214-3223.
25. Herrmann ME, LiVolsi VA, Pasha TL, et al. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med. 2002;126:710-713.
26. Mazzanti C, Zeiger MA, Costouros NG, et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 2004;64:2898-2903.
27. Rosai J. Immunohistochemical markers of thyroid tumors: significance and diagnostic applications. Tumori. 2003;89:517-519.
28. Raphael SJ. The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia. Endocr Pathol. 2002;13:301-311.
29. Smida J, Salassidis K, Hieber L, et al. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. Int J Cancer. 1999;80:32-38.
30. Cheung CC, Carydis B, Ezzat S, et al. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab. 2001;86:2187-2190.
31. Wirtschafter A, Schmidt R, Rosen D, et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope. 1997;107:95-100.
32. Lacroix L, Mian C, Barrier T, et al. PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur J Endocrinol. 2004;151:367-374.
33. Volante M, Bozzalla-Cassione F, DePompa R, et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows. Arch. 2004;445:183-188.
34. Dwight T, Thoppe SR, Foukakis T, et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab. 2003;88:4440-4445.
35. Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2002;87:3947-3952.
36. Tuccari G, Barresi G. Immunohistochemical demonstration of ceruloplasmin in follicular adenomas and thyroid carcinomas. Histopathology. 1987;11:723-731.
37. Yossie Asato de Camargo R, Longatto Filho A, Alves VA, et al. Lactoferrin in thyroid lesions: immunoreactivity in fine needle aspiration biopsy samples. Acta Cytol. 1996;40:408-413.
38. Ross JS, del Rosario AD, Sanderson B, et al. Selective expression of CD44 cell-adhesion molecule in thyroid papillary carcinoma fine-needle aspirates. Diagn Cytopathol. 1996;14:287-291.
39. Komminoth P, Seelentag WK, Saremaslani P, et al. CD44 isoform expression in the diffuse neuroendocrine system. II. Benign and malignant tumors. Histochem Cell Biol. 1996;106:551-562.
40. Tallini G. Molecular pathobiology of thyroid neoplasms. Endocr Pathol. 2002;13:271-288.
41. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002;13:3-16.
42. Ippolito A, Vella V, La Rosa GL, et al. Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy. Thyroid. 2001;11:783-787.
43. Zanetti A, Stoppacciaro A, Marzullo A, et al. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid. J Pathol. 1998;186:287-291.
44. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:5175-5180.
45. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science. 2000;289:1357-1360.
46. Cheung L, Messina M, Gill A, et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2003;88:354-357.
47. Ho YS, Tseng SC, Chin TY, et al. p53 gene mutation in thyroid carcinoma. Cancer Lett. 1996;103:57-63.
48. Fabbro D, Di Loreto C, Beltrami CA, et al. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res. 1994;54:4744-4749.
49. Suzuki S, Fukushima T, Ami H, et al. New attempt of preoperative differential diagnosis of thyroid neoplasms by telomerase activity measurement. Oncol Rep. 2002;9:539-544.
50. Liou MJ, Chan EC, Lin JD, et al. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Cancer Lett. 2003;191:223-227.
51. Hashimoto T, Matsubara F, Mizukami Y, et al. Tumor markers and oncogene expression in thyroid cancer using biochemical and immunohistochemical studies. Endocrinol Jpn. 1990;37:247-254.
52. Yoshida K, Hamatani K, Koide H, et al. Preparation of anti-ras Mr 21,000 protein monoclonal antibodies and immunohistochemical analyses on expression of ras genes in human stomach and thyroid cancers. Cancer Res. 1988;48:5503-5509.
53. Rorive S, Eddafali B, Fernandez S, et al. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod Pathol. 2002;15:1294-1301.
54. Beesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002;41:236-243.
55. Mai KT, Bokhary R, Yazdi HM, et al. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes. Histopathology. 2002;40:133-142.
56. Raphael SJ, McKeown-Eyssen G, Asa SL. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors. Mod Pathol. 1994;7:295-300.
57. Nishimura R, Yokose T, Mukai K. S-100 protein is a differentiation marker in thyroid carcinoma of follicular cell origin: an immunohistochemical study. Pathol Int. 1997;47:673-679.
58. Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998;58:3015-3020.
59. Saggiorato E, Cappia S, De Giuli P, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:5152-5158.
60. Abu-Alfa AK, Straus FH 2nd, Montag AG. An immunohistochemical study of thyroid Hürthle cells and their neoplasms: the roles of S-100 and HMB-45 proteins. Mod Pathol. 1994;7:529-532.
61. Erickson LA, Jin L, Wollan PC, et al. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol. 1998;11:169-174.
62. Tallini G, Garcia-Rostan G, Herrero A, et al. Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol. 1999;23:678-685.
63. Nascimento MC, Bisi H, Alves VA, et al. Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas. Endocr Pathol. 2001;12:275-279.
64. Kovacs RB, Foldes J, Winkler G, et al. The investigation of galectin-3 in diseases of the thyroid gland. Eur J Endocrinol. 2003;149:449-453.
65. Jakubiak-Wielganowicz M, Kubiak R, Sygut J, et al. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma. Pol J Pathol. 2003;54:111-115.
66. Cox JM. Applications of nylon membrane arrays to gene expression analysis. J Immunol Methods. 2001;250:3-13.
67. Jordan B. Historical background and anticipated developments. Ann N Y Acad Sci. 2002;975:24-32.
68. Hess KR, Zhang W, Baggerly KA, et al. Microarrays: handling the deluge of data and extracting reliable information. Trends Biotechnol. 2001;19:463-468.
69. Hornberg JJ, de Haas RR, Dekker H, et al. Analysis of multiple gene expression array experiments after repetitive hybridizations on nylon membranes. Biotechniques. 2002;33:108, 110, 112-113, passim.
70. Barden CB, Shister KW, Zhu B, et al. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res. 2003;9:1792-1800.
71. Kothapalli R, Yoder SJ, Mane S, et al. Microarray results: how accurate are they? BMC Bioinformatics. 2002;3:22.
72. Mah N, Thelin A, Lu T, et al. A comparison of oligonucleotide and cDNA-based microarray systems. Physiol Genomics. 2004;16:361-370.
73. Hwang KB, Kong SW, Greenberg SA, et al. Combining gene expression data from different generations of oligonucleotide arrays. BMC Bioinformatics. 2004;5:159.
74. Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med. 2003;3:659-671.
75. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002;94:513-521.
76. Kendziorski CM, Zhang Y, Lan H, et al. The efficiency of pooling mRNA in microarray experiments. Biostatistics. 2003;4:465-477.
77. Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol. 2002;30:503-512.
78. Baloch ZW, LiVolsi VA. The quest for a magic tumor marker: continuing saga in the diagnosis of the follicular lesions of thyroid. Am J Clin Pathol. 2002;118:165-166.
79. Johnson MR, Wilkin DJ, Vos HL, et al. Characterization of the human extracellular matrix protein 1 gene on chromosome 1q21. Matrix Biol. 1997;16:289-292.
80. Wang L, Yu J, Ni J, et al. Extracellular matrix protein 1 (ECM1) is overexpressed in malignant epithelial tumors. Cancer Lett. 2003;200:57-67.
81. Mongiat M, Fu J, Oldershaw R, et al. Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem. 2003;278:17491-17499.
82. Han Z, Ni J, Smits P, et al. Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. Faseb J. 2001;15:988-994.
83. Deckers MM, Smits P, Karperien M, et al. Recombinant human extracellular matrix protein 1 inhibits alkaline phosphatase activity and mineralization of mouse embryonic metatarsals in vitro. Bone. 2001;28:14-20.
84. Pauws E, Veenboer GJ, Smit JW, et al. Genes differentially expressed in thyroid carcinoma identified by comparison of SAGE expression profiles. Faseb J. 2004;18:560-561.
85. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev. 2001;11:41-47.
86. Netzel-Arnett S, Hooper JD, Szabo R, et al. Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metastasis Rev. 2003;22:237-258.
87. Wallrapp C, Hahnel S, Muller-Pillasch F, et al. A novel transmembrane serine protease (TMPRSS3) overexpressed in pancreatic cancer. Cancer Res. 2000;60:2602-2606.
88. Geng JG, Chen M, Chou KC. P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. Curr Med Chem. 2004;11:2153-2160.
89. Kim YJ, Borsig L, Varki NM, et al. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A. 1998;95:9325-9330.
90. Roselli M, Mineo TC, Martini F, et al. Soluble selectin levels in patients with lung cancer. Int J Biol Markers. 2002;17:56-62.
91. Blann AD, Gurney D, Wadley M, et al. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis. 2001;12:43-50.
92. Schadendorf D, Diehl S, Zuberbier T, et al. Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology. 1996;192:89-93.
93. Winzer R, Schmutzler C, Jakobs TC, et al. Reverse transcriptase- polymerase chain reaction analysis of thyrocyte-relevant genes in fine-needle aspiration biopsies of the human thyroid. Thyroid. 1998;8:981-987.
94. Takano T, Miyauchi A, Matsuzuka F, et al. Preoperative diagnosis of medullary thyroid carcinoma by RT-PCR using RNA extracted from leftover cells within a needle used for fine needle aspiration biopsy. J Clin Endocrinol Metab. 1999;84:951-955.